Home >> Tag Archives: GenomeDx Biosciences—

Tag Archives: GenomeDx Biosciences—

GenomeDx, Pathnostics distribution agreement, 11/17

November 2017—GenomeDx Biosciences and Pathnostics announced a strategic agreement for GenomeDx to distribute Pathnostics’ Guidance UGx for urinary tract infections and Guidance PRx for prostatitis. These molecular diagnostic tests detect the genomic sequence of pathogens, providing a faster and more comprehensive solution for physicians and their patients.

Read More »

Assay for subtyping MIBC, 8/17

August 2017—GenomeDx Biosciences launched its Decipher Bladder Cancer Classifier following the publication of a study in European Urology (Seiler R, et al. Epub ahead of print April 5, 2017) supporting its development and validation. The company believes Decipher Bladder is the first commercially available clinical assay to subtype muscle-invasive bladder cancer with a high degree of accuracy.

Read More »
X